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OBJECTIVE
A recent study raises concerns that dipeptidyl peptidase 4 inhibitors (DPP4i) are
associated with increased risk of inflammatory bowel disease (IBD). We evaluated
the association between new use of DPP4i and IBD risk compared with other second-
line antihyperglycemics.
RESEARCH DESIGN AND METHODS
We implemented an active-comparator, new-user cohort design using two U.S.
administrative claims databases for commercially insured (MarketScan) and older
adult (Medicare fee-for-service, 20% random sample) patients from January 2007
to December 2016. We identified patients, aged ‡18 years, who initiated DPP4i ver-
sus sulfonylureas (SUs) or initiated DPP4i versus thiazolidinediones (TZDs) and were
without prior diagnosis, treatment, or procedure for IBD. The primary outcomewas
incident IBD, defined by IBD diagnosis preceded by colonoscopy and biopsy
and followed by IBD treatment. We performed propensity score weighting to con-
trol for measured baseline confounding, estimated adjusted hazard ratios (aHRs
[95% CI]) using weighted Cox proportional hazards models, and used random-
effects meta-analysis models to pool aHRs across cohorts.
RESULTS
We identified 895,747 eligible patients initiating DPP4i, SU, or TZD; IBD incidence
rates ranged from 11.6 to 32.3/100,000 person-years. Over a median treatment
duration of 1.09–1.69 years, DPP4i were not associated with increased IBD risk
across comparisons. The pooled aHRs for IBD were 0.82 (95% CI 0.41–1.61) when
comparing DPP4i (n 5 161,612) to SU (n 5 310,550) and 0.76 (0.46–1.26) when
comparing DPP4i (n 5 205,570) to TZD (n 5 87,543).
CONCLUSIONS
Our population-based cohort study of U.S. adults with diabetes suggests that short-
term DPP4i treatment does not increase IBD risk.
Dipeptidyl peptidase 4 inhibitors (DPP4i), a commonly prescribed second-line
glucose-lowering drug (GLD) class, reduce hyperglycemia by increasing the levels
of incretin hormones, which in turn increase insulin and decrease glucagon in a
glucose-dependent fashion (1). DPP4, also known as CD26, is expressed on leukocytes
and can inactivate various cytokines as well as act as a costimulator of T lymphocytes
(2), thus raising concerns about potential immunologic effects of DPP4i (3). A recent
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retrospective cohort study by Abrahami
et al. (4) involving 141,170 patients in
the British Clinical Practice Research
Datalink (CPRD) database found that,
over a median use period of 1.6 years
and follow-up of 3.6 years, new use of
DPP4i was significantly associated with
an increased incidence of inflammatory
bowel disease (IBD) compared with
other GLDs (hazard ratio [HR] 1.75
[95% CI 1.22–2.49]), with HR 2.23
(1.32–3.76) for ulcerative colitis (UC)
and HR 0.87 (0.37–2.09) for Crohn dis-
ease (CD), respectively.
To date, the study by Abrahami et al.
(4) is theonly cohort studyavailableasses-
sing DPP4i’s IBD risk. Other studies have
yieldeduncertainty regarding theeffectof
DPP4i on IBD risk, which necessitates
replication using multiple sources and
study designs. While a meta-analysis of
randomized trials suggests no association
between DPP4i and IBD risk (5), a dis-
proportionality analysis of the U.S. Food
and Drug Administration Adverse Event
Reporting System database suggested a
weak to moderate signal of CD; the re-
porting odds ratio ($2 defined as a
positive signal) was 2.63 (95% CI 1.74–
3.99) compared with a comparator group
consisting of both thiazolidinediones (TZDs)
and sodium–glucose cotransporter 2 in-
hibitors (6). A cross-sectional analysis
of health care databases in Israel also
suggests a signal for CD (odds ratio 3.56
[1.04–12.21]) (7). Given these results, we
conducted a retrospective cohort study,
using the active-comparator, new-user
(ACNU) cohort design (8), to address the
methodological limitations of prior stud-
ies and to further investigate whether
new use of DPP4i is associated with an
increased risk of IBD.
RESEARCH DESIGN AND METHODS
Data Source
We used two large U.S.-based admin-
istrative claims databases: the IBM
MarketScan Commercial Claims and
Encounters (MarketScan) and a 20%
random sample (University of North
Carolina at Chapel Hill has access
for only 20% random sample) of Medi-
care Fee-for-Service (Medicare) from
January 2007 to December 2016. The
MarketScan database contains data
primarily on adults aged ,65 years
from ;350 insurance payers across the
U.S. Medicare provides medical cover-
age primarily for the U.S. population
aged $65 years, including Parts A (in-
patient), B (outpatient physician ser-
vices), andD (dispensedprescriptiondrugs)
coverage. Both databases contain longi-
tudinal, individual-level data, including
demographics, inpatient and outpatient
diagnosis and procedures, and pharmacy
claims. The study protocol was registered
in the European Network of Centres for
Pharmacoepidemiology andPharmacovigi-
lance electronic register of studies (http://
www.encepp.eu/encepp/viewResource
.htm?id526246) and approved by the
University of North Carolina at Chapel Hill
Institutional Review Board.
Study Population
The eligible population consisted of
MarketScan enrollees, aged 18–64 years,
as well as Medicare enrollees, aged $65
years, both with at least 12 months of
continuous enrollment (for Medicare,
continuous enrollment in Parts A, B,
and D and without HMO coverage) be-
fore initiation. We first independently
identified all new use periods from 1
January 2008 to 30 September 2015 of
each of the three second-line therapies
of interest (9)dDPP4i, sulfonylureas
(SUs), and thiazolidinediones (TZDs)d
simultaneously (i.e., the three groups
of new users are not mutually exclusive)
based on the first dispensing of a pre-
scription in a given drug class after a
12-month washout period. A patient
could have multiple new-user periods
of the same drug class and could enter
the study in both drug classes (after at
least 12 months with no prescription fill
after the end of the days’ supply of a
previous prescription fill or after the start
of enrollment). Then, we constructed
two comparison cohorts from the three
groups of new usersdDPP4i versus SU
and DPP4i versus TZD, additionally re-
quiring no evidence of use of the com-
parator drug in the 12 months prior to
initiation (therefore, the number of par-
ticipants and events for DPP4i differed
in the two comparisons). We used two
comparators, as both are oral treat-
ment alternatives, thereby increasing
the clinical relevance by addressing
the question, “which second-line treat-
ment is safer?” Additionally, we required
patients to have a second prescription-
dispensing claim within the sum of the
first prescription’s days’ supply and a
90-day grace period to increase the
probability that patients actually took
the medication (10). The use of active
comparators helps to reduce bias by
only selecting individuals at similar dis-
ease severity and with an indication for
initiating a second-line GLD, and the
new-user design ensures appropriate
temporal ordering of baseline confound-
ers, treatment, and outcome (8). We did
not restrict cohorts to those with a di-
agnosis code for diabetes, as these GLDs
are primarily indicated for diabetes
treatment (9).
We excluded patients with the follow-
ing diagnoses, treatments, or procedures
in the 12 months before the first pre-
scription (index date):1) diagnosis of IBD,
including CD and UC; 2) prior exposure
to IBD treatments, including aminosalicy-
lates, anti–tumor necrosis factor, enteral
budesonide, and immunosuppressive/
immunoregulatory agents (11,12); 3)
commondiseases that could be confused
with IBD, including diverticulitis, ische-
mic colitis, pseudomembranous colitis,
or unspecific colitis; 4) prior colectomy,
colostomy, ileostomy, or receipt of os-
tomy supplies; and 5) prior colonoscopy
or sigmoidoscopy before 50 years of age
(because current U.S. Preventative Ser-
vices Task Force guidelines recommend
colonoscopy for colorectal cancer only
for individuals aged 50–75 years [13]).
We additionally excluded patients with
a diagnosis of congestive heart failure
when comparing DPP4i to TZDs (TZDs are
contraindicated in patients with heart
failure [14]).
IBD Outcome
The primary outcome was incident IBD,
defined by the first IBD diagnosis (ICD-9
and ICD-10, Clinical Modification codes)
that was preceded by a colonoscopy/
sigmoidoscopy and biopsy within 30 days
before diagnosis and followed by a pre-
scription claim for IBD medication treat-
ment within 30 days after diagnosis
(Supplementary Tables 1 and 2A). The
date of IBD diagnosis was considered as
the event date. Secondary analyses as-
sessed the risk of incident CD and UC,
respectively. The majority of the first
three diagnoses were used to distinguish
between CD and UC.
Follow-up
Because short duration of exposure is
unlikely to be associated with incident
IBD, and IBD diagnosis is unlikely to be
made immediately after symptom onset
(15), we started follow-up for the out-
come 180 days (induction period) after
the second prescription (cohort entry
date) and excluded patients with the
outcome or discontinued enrollment
within 180 days after their second pre-
scription. Similarly, follow-up for IBD
events continued 180 days (latency pe-
riod) after treatment was changed or
stopped. Follow-up ended at the earliest
of the following events: 1) 180 days after
the date of treatment change, including
discontinuation (defined as no refill
within a period equal to the prescribed
days’ supply of the last filled prescription
plus a 90-day grace period) or initiating
the comparator drug (initiating noncom-
parator GLDs would not result in cen-
soring); 2) the end of enrollment (the end
of enrollment for Parts A, B, or D or
enrollment for HMO for Medicare ben-
eficiaries); 3) death (for Medicare only);
4) administrative study end (31 Decem-
ber 2016); or 5) observation of an in-
cident IBD event, per the definition
above. We used the first incident IBD
event date during follow-up to define the
outcome date.
Statistical Analyses
We controlled for a variety of covariates
defined based on claims during the
12 months prior to the index prescrip-
tion (Supplementary Table 3), including
demographics, markers for diabetes
severity (retinopathy, nephropathy,
and neuropathy), gastroenterological
disease, autoimmune disease, comor-
bidities, comedications, health care
utilization (e.g., gastroenterologist
encounters), appendectomy, and low-
income subsidy status (for Medicare
only) (11,12,16). To control for factors
that may influence the decision to
prescribe a given treatment, we used
these covariates to estimate propensity
scores (PSs) for each patient in each
comparison. The PS, which represents
the predicted probability of receiving the
index treatment conditional on baseline
covariates, was estimated separately for
each comparison. We then applied asym-
metric PS trimming in order to exclude
patientswhowere treatedmost contrary
to prediction (i.e., in the tails of the PS
distribution), using a cut point corre-
sponding to the 0.5th and 99.5th per-
centiles of the PS distribution in the
treated and untreated patients, respec-
tively (17).
To directly compare the estimates
across two comparator groups for
each of the DPP4i comparisons, we stan-
dardized the covariate distribution of
comparator initiators to the covariate
distribution of DPP4i initiators using
standardized mortality/morbidity ratio
(SMR) weights (PS/[1 2 PS]) (18). SMR
weighting aims to create comparator
cohorts with the same covariate distri-
bution as the DPP4i cohort, allowing for
the estimation of the average treatment
effect in the treated. This allowed us to
estimate what would have happened to
the actual DPP4i initiators if they had,
contrary to fact, initiated the comparator
drug class instead. We measured covar-
iate balance using SDs between cohorts,
with SDs ,0.1 (10%) after weighting
indicating successful control for mea-
sured confounding.
We calculated crude incidence rates by
dividing the number of patients with
observed outcome by the total amount
of observed person-time for each expo-
sure cohort, with 95% CIs estimated us-
ing Poisson regression. We constructed
SMR-weighted (adjusted) Kaplan-Meier
curves to compare the cumulative in-
cidence of IBD (19) and fit Cox propor-
tional hazards models in the PS-weighted
populations to estimate adjusted HRs
(aHRs) and 95% CIs for IBD associated
with initiating DPP4i versus comparators.
Finally, we performed a meta-analysis of
both estimates from MarketScan and
Medicare data using random-effects
models with inverse variance weight-
ing (20) to report pooled HRs (pHRs); a
fixed-effects model was used for sensitiv-
ity analysis. Between-database hetero-
geneity was assessed using I2 statistics
(21), which represents the proportion of
the total variance in the meta-analysis
that is attributed to between-database
heterogeneity.
Secondary Analyses
We stratified analyses by age at cohort
entry (aged ,50 and $50 years in
MarketScan and ,75 and $75 years in
Medicare), sex, duration of treatment
(#12 and.12 months), and preexisting
gastroenterological disease (as patients
with preexisting conditions tend to have
more physician visits and thus a higher
chance for IBD diagnosis). We also re-
stricted to patients without autoimmune
disease at baseline (only ;5% had
preexisting autoimmune disease). Finally,
we estimated IBD risk for each individual
DPP4i agent (sitagliptin, saxagliptin, and
linagliptin).
Sensitivity Analyses
To assess the robustness of estimated
IBD risk, we performed the following
sensitivity analyses based on our primary
analysis (as-treated, second prescription
as cohort entry date, using a 180-day lag
for both induction and latency periods)
unless stated otherwise. First, we re-
peated the analyses of IBD and the
IBD subtypes CD and UC changing
both induction and latency periods
from 180 days to 0 days, 90 days, and
365 days. Second, we performed initial-
treatment analysis ignoring treatment
changes during follow-up, which mimics
the intention-to-treat analysis in a ran-
domized trial. The follow-upended at the
earliest of the following events: death
(Medicare only), the end of insurance
enrollment, end of study, or an incident
IBD event. We also stratified by time
since the first prescription (#2, .2–4,
and .4 years) in these initial-treatment
analyses. Third, we required only one
study drug prescription in the exposure
definition and used the first prescription
as cohort entry date (i.e., follow-up
started 180 days after the first prescrip-
tion and ended 180 days after treatment
change). Fourth, we constructed cohorts
using only the first new-user period
(i.e., patients could only enter the cohort
once) and reconstructed Kaplan-Meier
curves. Fifth, we applied the abovemen-
tioned exclusion criteria (IBD diagnoses,
treatments, or procedures) in the all-
available look-back history before the
first prescription. Sixth, we modified our
primary outcome (Supplementary Fig. 2)
to: 1) use the date of IBD treatment
instead of the date of IBD diagnosis as
event date, to quantify the potential for
time-related bias; 2) remove the biopsy
requirement; 3) removeboth colonoscopy/
sigmoidoscopy and biopsy require-
ments; and 4) define patients with IBD
as those with at least three diagnoses
on different days within 90 days (22), in
which the third diagnosis date was
considered as the event date. Seventh,
we relaxed our exclusion criteria
to include additional patients with: 1)
prior use of the abovementioned IBD
treatments except mesalamine and en-
teral budesonide; 2) prior partial colec-


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































supplies; and 3) MarketScan patients
who received colonoscopy/sigmoidoscopy
prior to 50 years of age. Eighth, we
additionally censored patients when
they received medications that could
potentially induce or progress IBD (23)
(Supplementary Table 2B). Ninth, we
conducted conventional multivariable-
adjusted Cox regression instead of
PS-weighted Cox regression to control
for potential confounders. Lastly, we
excluded patients who originally quali-
fied for Medicare due to end-stage renal
disease and disability. All database-
specific analyses described above
were performed using SAS version
9.4. Meta-analyses were conducted
using STATA version 14.0.
RESULTS
Study Population
Across the two databases, we identified
896,084 eligible patients who filled at
least two prescriptions for each cohort
drug, including 382,475 (MarketScan)
and 170,326 (Medicare) initiators for
the DPP4i versus SU comparison and
249,750 (MarketScan) and 93,533 (Medi-
care) initiators for the DPP4i versus TZD
comparison (Supplementary Fig. 3). The
key baseline covariates are shown in
Table 1. The mean age ranged between
51.0 and 74.8 years; 40.8–58.2% were
men. Patients were more likely to have
been treated with DPP4i compared
with TZD since 2011. Overall, the prev-
alence of comorbidities was similar in
the comparison cohorts, except that
DPP4i initiators were more likely to
have dyslipidemia and take metformin
as background therapy. In the Medicare
population, DPP4i initiators had more
physician visits and more health care
utilization (e.g., more likely to take
flu shot). In the third column of each
comparison (Table 1), we present PS-
weighted covariate distributions for the
comparator drug initiators. The well-
balanced distribution of the covariates
in DPP4i initiators and the PS-weighted
comparator initiators (allweighted stan-
dardized absolute mean differences,0.1;
the proportion of standardized absolute
mean difference,0.01 was 63% for DPP4i
vs. SU and 76% for DPP4i vs. TZD inMarket-
Scan and 98% for DPP4i vs. SU and 79% for
DPP4i vs. TZD inMedicare) shows thatwe
were able to balance all measured covar-
iates and, thus, remove measured con-
founding by these covariates.
DPP4i and IBD
In Table 2, we present results of the
primary as-treated analysis for IBD risk.
Among the eight cohorts, the observed
number of events ranged from ,11 to
53, and the median treatment duration
ranged from 1.09 to 1.69 years with an
average duration of 1.71 years. Crude
incidence of IBD ranged from 11.6 to
32.3 events/100,000 person-years, and
average incidence was 22.0/100,000
person-years. After adjustment for con-
founding, DPP4i was not associated
with increased risk of IBD. The esti-
mated pHR was 0.82 (95% CI 0.41–
1.61) when comparing DPP4i (n 5
161,612) to SU (n 5 310,550) and
0.76 (0.46–1.26) when comparing
DPP4i (n 5 205,570) to TZD (n 5
87,543) (Supplementary Fig. 5). The me-
dian time between first and second pre-
scriptions ranged from 32 to 35 days, the
median number of prescriptions during
follow-up ranged from 8 to 12, and the
majority of patients were censored due
to end of enrollment and discontinua-
tion of treatment (Supplementary Tables
4A–C). Weighted Kaplan-Meier curves
for each database demonstrated similar
patterns; CI bands are wide, especially for
TZD (Fig. 1).
Results for secondary analyses are
shown in Fig. 2. Compared with SU,
DPP4i showed a trend for increased risk
for CD (pHR 1.22 [95% CI 0.60–2.47]).
With stratification by age, we observed
a higher HR in younger patients in the
MarketScan population. DPP4i showed
a lower risk versus SU in patients with
preexisting gastrointestinal disease
(pHR 0.39 [0.14–1.07]), and a lower
risk versus TZD in women (pHR 0.53
[0.26–1.06]). Overall, the pHRs did not
differ meaningfully in stratified analysis
and CIs widely overlapped.
Sensitivity Analyses
Overall, sensitivity analysis results for
IBDwere consistent with our primary anal-
ysis (Fig.2);detailedresults foreachanalysis
were shown in the Supplementary Data.
Weighed Kaplan-Meier curves for the first
new-user period–based cohort (Supple-
mentary Fig. 19B) showed a pattern similar
to that of the primary analysis. In initial-
treatment analysis, the median follow-up
time ranged from 1.78 to 3.86 years, with
an average follow-up time of 2.58 years.
When stratified by time since initiation, pHR
reached a peak between 2 and 4 years
after initiation (pHR 1.24 [0.54–2.89] vs. SU
and 1.73 [0.85–3.49] vs. TZD, respectively)
and then decreased after 4 years.
CONCLUSIONS
Summary
Our study examined data from two large
U.S. databases and observed no evidence
of increased risk of IBD for DPP4i com-
paredwith therapeutic alternatives, over
an average treatment duration of;1.5–
2 years. Instead, we observed effect
estimates that suggested a possibility
of decreased IBD risk in new use of
DPP4i compared to TZD. The results
were robust across secondary and sen-
sitivity analyses.
DPP4i and IBD Risk
Our results are in line with the recent
meta-analysis of randomized trials (5),
which reported similar IBD risk between
DPP4i users and comparators (relative
risk 1.01 [0.31–3.41] over a duration of
2.4 years). Notably, we observed slightly
decreasedpHRsofDPP4i comparedwith
therapeutic alternatives, especially ver-
sus TZD, suggesting the possibility of a
protective effect. This is consistent with
previous studies on mouse models sug-
gesting that DPP4i can lead to decreased
IBD activity (24–28). A proposed role for
DPP4i as a novel pharmacological agent
for IBD is based in its anti-inflammatory
and immunomodulatory effects. An in-
teraction between the DPP4i and DPP4 is
essential for a reduced inflammatory
response, and DPP4 expressed on the
cell surface is critical for DPP4i’s immu-
nomodulatory effects (25).
However, some clinical data also sug-
gest that patients with IBD have lower
serum DPP4 concentration, which is
inversely associated with increased IBD
activity, and it is undetermined whether
the lower serum DPP4 is the conse-
quence or cause of IBD (29–31). We
also detected a weak signal for increased
CD risk of initiating DPP4i versus SU
and a trend for increased risk between
2 and 4 years after initiation in the initial-
treatment analysis. Thus, a more com-
plex mechanism may exist, and future
studies are needed to investigate effects
of DPP4i on IBD.
Comparison With Previous Studies
Our results are consistent with the recent
meta-analysis of 13 trials (5). Both cross-
sectional analyses suggested weak to
moderate signal (6,7); however, pharma-
covigilance databases are prone to re-
porting bias and cannot be used to assess
incident IBD.
The CPRD study by Abrahami et al. (4)
suggested an increased risk of both IBD
(HR 1.75 [95% CI 1.22–2.49]) and UC (HR
2.23 [1.32–3.76]) associated with DPP4i
use. The risk appeared to increase be-
tween 2 and 4 years after treatment
initiation, and there was no significant
association in the first 2 years or after
4 years of use. No signal for CD (HR 0.87
[0.37–2.09]) was detected. In contrast,
our study did not suggest an association
between DPP4i initiation and IBD risk,
and we observed a weak signal only for
CD. We also observed a trend for an
increased risk between 2 and 4 years
after initiation in our initial-treatment
analysis.
Our study differed from the CPRD
study in several ways, including exclusion
criteria, outcome definition, study
design, covariates, study population,
and follow-up time. We found no mean-
ingful difference between treatments in
sensitivity analyses in which we relaxed
exclusion criteria and used less specific
outcome definitions that were similar to
the CPRD study. Notably, the follow-up
time for our initial-treatment analysis
(pertinent information to allow for a com-
parison) was shorter than the CPRD study.
Additionally, the inconsistent results may
be due to differences in study design and
analysis choices.
In our ACNU cohort, we compared
DPP4i to other second-line treatments,
SU or TZD, which may be a more reason-
able choice, as it leads to less clinical
heterogeneity between index and com-
parator groups and therefore reduces
the potential for unmeasured confound-
ing. Our ACNU design also requires a
washout period before initiating therapy
for DPP4i and comparator drug classes,
which minimizes bias from treatment
choice affected by previous treatment
(other GLDs that may influence subsequent
prescribing are balanced by PSs). Both
DPP4i and comparator initiators were an-
alyzed in the same fashion (i.e., in either
as-treated [censoring patients who initiated
the other drug in the drug pair that is
being compared] or initial-treatment [ig-
noring treatment changes] analysis).
By comparison, the CPRD study (4)
compared DPP4i with non-DPP4i GLDs,















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Moreover, patients were allowed to
switch from comparator to DPP4i after
cohort entry but not the other way
around (thereby allowing the same pa-
tient to contribute unexposed and then
exposed person-time, but not vice versa).
Although DPP4i users and nonswitchers
were analyzed by initial-treatment anal-
ysis, those switchers were handled in
an as-treated fashion (censored when
switching) and then were included in
the DPP4i group and analyzed in initial-
treatment fashion (Supplementary Fig.
26). Therefore, DPP4i and comparator
groups were not actually analyzed in the
same way. A proper initial-treatment
analysis handles both treatment cohorts
in the same manner (i.e., ignoring treat-
ment changes in both groups), which
in turn avoids selection bias. Considering
the high switching rate among second-
line GLD users in CPRD data (;45% at
18 months [32]), a large proportion of
patients likely switched to DPP4i in the
CPRD study. Such switchers may be af-
fectedbyprevious therapydfor example,
physicians may switch patients on met-
formin or glucagon-like peptide 1 recep-
tor agonists to DPP4i due to development
of gastrointestinal symptoms (whichmay
be either drug adverse events [33] or
early symptoms of IBD). Notably, in a
head-to-head comparison of the CPRD
study, a higher risk was also observed
comparing DPP4i versus insulin (HR 2.28
[1.07–4.85]), which might be due to a
speculative potential protective effect of
insulin on UC (34).
Limitations
Our findings should be viewed in light of
limitations. First, we had no information
on diabetes duration, and data on mea-
sures of glycemic control were available
for only a small proportion of the pop-
ulation. The presence of risk factors, such
as smoking, in claims data has high
specificity but low sensitivity (35). How-
ever,Wanget al. (36) havedemonstrated
that clinical measures such as hemoglo-
bin A1c are well balanced between DPP4i
versus SU and DPP4i versus TZD compar-
isons in their ACNU study.
Second, our algorithm for detection of
the outcome has not been validated.
However, it is unlikely that cases that
met our disease definition (with colono-
scopy, biopsy, and treatments) are not
incident IBD. A high-specificity outcome
definitionminimizes bias in the HR, even in
the presence of nonperfect sensitivity (37).
Third, we only assessed short-term
DPP4i use (average duration 1.71 years)
Figure 1—SMR-weighted Kaplan-Meier plots of IBD: DPP4i vs. SU cohort in MarketScan (A), DPP4i vs. SU cohort in Medicare (B), DPP4i vs. TZD cohort
in MarketScan (C), and DPP4i vs. TZD cohort in Medicare (D). Follow-up started for the outcome 180 days (induction period) after the second prescription
(cohort entry date). SMRweights create a pseudopopulation of the untreated (comparators: SU or TZD), which has the same covariate distribution as the
treated (DPP4i). Everypatient receivingDPP4ihasaweightof1,whileeverypatient in thecomparatorgroup isweightedby (PS/[12PS]). Theriskson the
y-axis were obtained by SMR-weighted Cox model (weighting comparator drug initiators by the PS odds [PS/(12 PS)]). HR treating comparators as
reference; aHR ,1 indicates a lower risk for DPP4i. Dotted lines around the survival curve point estimates represent 95% CI bands. *HR 1.08 (95%
CI 0.70–1.68); †HR 0.53 (0.24–1.15); ‡HR 0.68 (0.37–1.26); §HR 0.97 (0.40–2.37).
because real-world adherence and per-
sistence are low (10), which may impair
the potential for detecting differences
with long-term use of these drugs, and
our conclusion is only generalizable
to short-term use. Censoring treat-
ment change in the primary analysis
is a potential source of selection bias.
As information that drives treatment
decisions (e.g., laboratory data or subtle
side effects) is oftenmissing in secondary
databases, we did not predict adherence
or use inverse probability of censor-
ing weights to address censoring ana-
lytically. Our initial-treatment analysis
ignoring treatment change avoids selec-
tion bias and yielded similar results, but
we cannot necessarily rule out the pos-
sibility that informative censoring has
affected results of our primary analysis.
Lastly, our ACNU cohorts are a selec-
tion of DPP4i initiators with no recent
history of comparator drug use and
thereforedonot cover all DPP4i initiators
in the real world. Using a 12-month
baseline period and including multiple
new-user periods that meet the wash-
out period cannot completely rule out
prevalent IBD. However, our analyses
for only the first new-user period and
Kaplan-Meier plots are consistent with
primary analysis, suggesting no immortal-
time bias. In addition, all available look-
back history–based cohorts also yielded
similar results, indicating that the inclu-
sion of patients with prevalent IBD was
not a major limitation. We therefore
do not believe that such biases played
a major role in our results.
In conclusion, our population-based,
ACNU cohort study of older U.S. adults
with diabetes suggests that the short-
term real-world use of DPP4i does not
increase the risk of IBD compared with
second-line alternatives. This finding
should be reassuring to physicians and
patients who are considering the poten-
tial benefits and risks of DPP4i.
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